Evidence map›Paper›PMID 23519997›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2013

Granulocyte transfusions in hematologic malignancy patients with invasive pulmonary aspergillosis: outcomes and complications.

I I Raad, A M Chaftari, M M Al Shuaibi, Y Jiang, W Shomali, J E Cortes, B Lichtiger, R Y Hachem

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Innovation in antifungal therapy.EMBO molecular medicine · 2026
    Review
  3. Article
  4. Review
  5. Therapeutic Challenges of Non-Antimicrobial agents and chemotherapy · 2019
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

I I RaadDepartments of Infection Control, Infectious Diseases and Employee Health. Electronic address: iraad@mdanderson.org.
A M ChaftariDepartments of Infection Control, Infectious Diseases and Employee Health.
M M Al ShuaibiDepartments of Infection Control, Infectious Diseases and Employee Health.
Y JiangDepartments of Infection Control, Infectious Diseases and Employee Health.
W ShomaliDepartments of Infection Control, Infectious Diseases and Employee Health.
J E CortesDepartment of Leukemia.
B LichtigerDepartment of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
R Y HachemDepartments of Infection Control, Infectious Diseases and Employee Health.
The University of Texas MD Anderson Cancer Center · USUnited States Department of Health and Human Services · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGranulocyte transfusions (GTXs) have been used successfully as an adjunctive treatment option for invasive infections in some neutropenic patients with underlying hematologic malignancy (HM). PATIENTS AND

methodsWe sought to determine the impact of GTX as an adjunct to antifungal therapy in 128 patients with HM and prolonged neutropenia (≥14 days) with a proven or probable invasive aspergillosis (IA) infection by retrospectively reviewing our institutional database.

resultsFifty-three patients received GTX and 75 did not. By univariate analysis, patients with invasive pulmonary aspergillosis who received GTX were less likely to respond to antifungal therapy (P = 0.03), and more likely to die of IA (P = 0.009) when compared with the non-GTX group. Among patients who received GTX, 53% developed a pulmonary reaction. Furthermore, IA-related death was associated with the number of GTX given (P = 0.018) and the early initiation of GTX within 7 days after starting antifungal therapy (P = 0.001). By multivariate competing risk analysis, patients who received GTX were more likely to die of IA than patients who did not receive GTX (P = 0.011).

conclusionsOur study suggests that GTX does not improve response to antifungal therapy and is associated with worse outcomes of IA infection in HM patients, particularly those with pulmonary involvement.

Indexed as

AdolescentAdultAgedAged, 80 and overAntifungal AgentsCell TransplantationChildFemaleGranulocytesHumansInvasive Pulmonary AspergillosisLeukemiaLymphomaMaleMiddle AgedMultivariate AnalysisAntifungal Agentsaspergillosisgranulocyte transfusionshematologic malignancy

Identifiers

PMID23519997
PMCPMC4990830
OpenAlexW2158752968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.